Title:
MARKERS FOR PROGRESSION OF INFLAMMATORY LIVER DISEASE
Document Type and Number:
WIPO Patent Application WO/2023/186997
Kind Code:
A3
Abstract:
The current invention provides biomarkers and combinations thereof for the diagnosis and prognosis of inflammatory liver disease. Methods include the biomarkers suppression of tumorigenicity 2 receptor (ST2), interleukin 6 (IL-6), interleukin 8 (IL-8), tumour necrosis factor alpha (TNFα) and Procollagen III N-terminal peptide (P3NP).
Inventors:
LAMONT JOHN (GB)
FITZGERALD PETER (GB)
RUDDOCK MARK (GB)
WATT JOANNE (GB)
FITZGERALD PETER (GB)
RUDDOCK MARK (GB)
WATT JOANNE (GB)
Application Number:
PCT/EP2023/058171
Publication Date:
November 23, 2023
Filing Date:
March 29, 2023
Export Citation:
Assignee:
RANDOX LABORATORIES LTD (GB)
International Classes:
G01N33/68
Other References:
JAMALI RAIKA ET AL: "Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines", MEDICINE, vol. 95, no. 5, 1 February 2016 (2016-02-01), US, pages e2630, XP093071611, ISSN: 0025-7974, DOI: 10.1097/MD.0000000000002630
GOYALE ATUL ET AL: "Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study", PLOS ONE, vol. 16, no. 11, 23 November 2021 (2021-11-23), pages e0260313, XP093071478, Retrieved from the Internet DOI: 10.1371/journal.pone.0260313
VEERAL AJMERA ET AL: "Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 65, no. 1, 12 October 2016 (2016-10-12), pages 65 - 77, XP071563026, ISSN: 0270-9139, DOI: 10.1002/HEP.28776
ZOBAIR M YOUNOSSI ET AL: "A Biomarker Panel for Non alcoholic steatohepatitis (NASH) and NASH relted fibrosis", OBES. SURG,, vol. 21, 8 June 2010 (2010-06-08), pages 431 - 439, XP002796004, DOI: 10.1007/S11695-010-0204-1
GAO YINJIE ET AL: "IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis", ONCOTARGET, vol. 7, no. 23, 7 June 2016 (2016-06-07), United States, pages 33649 - 33661, XP093071557, ISSN: 1949-2553, DOI: 10.18632/oncotarget.9259
GOYALE ATUL ET AL: "Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study", PLOS ONE, vol. 16, no. 11, 23 November 2021 (2021-11-23), pages e0260313, XP093071478, Retrieved from the Internet
VEERAL AJMERA ET AL: "Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 65, no. 1, 12 October 2016 (2016-10-12), pages 65 - 77, XP071563026, ISSN: 0270-9139, DOI: 10.1002/HEP.28776
ZOBAIR M YOUNOSSI ET AL: "A Biomarker Panel for Non alcoholic steatohepatitis (NASH) and NASH relted fibrosis", OBES. SURG,, vol. 21, 8 June 2010 (2010-06-08), pages 431 - 439, XP002796004, DOI: 10.1007/S11695-010-0204-1
GAO YINJIE ET AL: "IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis", ONCOTARGET, vol. 7, no. 23, 7 June 2016 (2016-06-07), United States, pages 33649 - 33661, XP093071557, ISSN: 1949-2553, DOI: 10.18632/oncotarget.9259
Download PDF:
Previous Patent: METHOD FOR REGISTERING A 3D MEDICAL IMAGE WITH A REGISTRATION PHANTOM
Next Patent: EXCISION TOOL FOR STERNAL FIXATION ELEMENTS
Next Patent: EXCISION TOOL FOR STERNAL FIXATION ELEMENTS